In the post-hoc analysis of phase 1/2 CodeBreaK 100 trial, Sotorasib demonstrated a great intracranial response in KRAS G12C-positive NSCLC patients with stable BMs, previously treated with either RT or surgery. This evidence concerns the gene KRAS and non-small cell lung carcinoma.